Le français est une traduction alpha automatisée. Pour le texte officiel, consultez la version anglaise.
Comparer
Comparer des captures archivées
Cette vue met en évidence des différences de texte entre deux captures archivées. Elle n’interprète pas le sens et ne fournit pas de directives.
Changements descriptifs seulement
Cette comparaison met en évidence des changements de texte entre des captures archivées. Elle n’interprète pas le changement et ne fournit pas d’avis médical. Pour des recommandations à jour, consultez toujours le site officiel de la source.
Besoin de citer cette comparaison? Voir /cite.
Capture précédente
Consultation on draft guidance on co-packaged drug products: Share your views - Canada.ca
18 avr. 2025
legacy-hc-2025-04-21
ID 147142
Capture suivante
Draft guidance on co-packaged drug products: Closed consultation - Canada.ca
2 janv. 2026
hc-20260101
ID 428988
Changement à bruit élevé
Ce changement peut inclure des mises à jour de mise en page ou de gabarit (par exemple : navigation ou pied de page). Traitez le diff comme descriptif, et non définitif.
--- +++ @@ -1,24 +1,19 @@-Share your views: Consultation on draft guidance on co-packaged drug products+Draft guidance on co-packaged drug products: Closed consultation From: Health Canada-Current status: Open-Opened on March 18, 2025, and will close to new input on May 18, 2025.-Health Canada has drafted a guidance document on co-packaged drug products. This document explains the regulatory requirements for co-packaged drug products and their components. This draft guidance is open for consultation.-Join in: how to participate-Send us an email-Send an email to-bpsip-bpspiconsultation@hc-sc.gc.ca-with your ideas or comments to make yourself heard.-Participate by mail-Send a letter with your ideas and input to the address in-contact information-below.-Who is the focus of this consultation-The Government of Canada would like to hear from all interested parties, including:+Current status: Closed+This consultation ran from March 18 to May 18, 2025.+Health Canada has drafted a guidance document on co-packaged drug products. This document explains the regulatory requirements for co-packaged drug products and their components.+Who was the focus of this consultation+Health Canada engaged with interested parties, including: manufacturers of co-packaged drug products and their components manufacturers, importers and distributors of all classes of medical devices included in a co-packaged drug product others involved in packaging, labelling, importing or selling co-packaged drug products health care professionals and associations+What we heard+To view the summary report of the consultation, see+What we heard: Draft guidance on co-packaged drug products+. Key points about the draft guidance This draft guidance explains the regulatory requirements for co-packaged drug products and their components. It: defines types of co-packaged products@@ -29,16 +24,5 @@ Learn more: Draft guidance on co-packaged drug products Health Canada drafts guidance on co-packaged drug products: Notice-Contact us-Bureau of Policy, Science and International Programs-Pharmaceutical Drugs Directorate-Health Products and Food Branch-Health Canada-1600 Scott St-Address Locator: 3106B-Ottawa ON K1A 0K9-Email:-bpsip-bpspiconsultation@hc-sc.gc.ca Page details-Date modified:-2025-03-18+2025-10-27